WebMar 13, 2024 · The specialty pharmaceutical company posted revenue of $60.7 million in the period. For the year, the company reported net income of $35.6 million, or $2.73 per share, swinging to a profit in the period. Revenue was reported as $316.6 million. Eagle Pharmaceuticals expects full-year earnings in the range of $4.20 to $4.53 per share. … WebEagle Pharmaceuticals Financials Summary financials Revenue ( Q3, 2024) $65.9M Gross profit ( Q3, 2024) $45.0M Net income ( Q3, 2024) ($7.1M) Cash ( Q3, 2024) …
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat …
WebMar 13, 2024 · Fourth Quarter 2024. Total revenue for Q4 2024 was $60.7 million, compared to $42.3 million in Q4 2024. Q4 2024 net income was $8.2 million, or $0.63 per basic and $0.62 per diluted share, compared to net loss of $ (6.2) million, or $ (0.48) per … WebApr 5, 2024 · Eagle Pharmaceuticals (NASDAQ:EGRX) has a market capitalization of $396.32 million and generates $316.61 million in revenue each year. The specialty … can chewable vetmedin be crushed
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2024 …
WebMar 13, 2024 · Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates Zacks Mar. 13, 2024, 08:05 AM Eagle Pharmaceuticals (EGRX) came out with quarterly earnings of $1.10 per share,... WebMay 9, 2024 · Q1 2024 total revenue was $115.9 million, up from $41.2 million in Q1 2024. Achieved sales of $34.3 million of vasopressin, with prior four weeks average market … WebMar 13, 2024 · Full Year 2024. Total revenue for the 12 months ended December 31, 2024 was $316.6 million, compared to $171.5 million, in 2024, an increase of 84.6%. Net income for the 12 months ended December 31, 2024 was $35.6 million, or $2.76 per basic and $2.73 per diluted share, compared to net loss of $ (8.6) million, or $ (0.66) per basic and … fish in light bulb photoshop tutorial